c-MPL
Synonyms
THPOR, MPL, TPOR, Myeloproliferative leukemia protein, Myeloproliferative Leukemia Virus Oncogene, Proto-Oncogene C-Mpl, TPO-R, CD110 Antigen, THCYT2, C-MPL, CD110, MPLV, Receptors, Thrombopoietin, MPL Proto-Oncogene, Thrombopoietin Receptor, Thrombopoietin Receptor
Description
c-MPL is the receptor for thrombopoietin (TPO), the main megakaryocyte (MK) growth factor, and c-Mpl is believed to be expressed on cells of the hematopoietic lineage. Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. May represent a regulatory molecule specific for TPO-R-dependent immune responses.
KO Status
F0
Drug Information
Launched drugs: 6
Drugs in clinical trials: 8
Latest Research Phase: Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Lusutrombopag
S-888711
Approved
Shionogi & Co Ltd
Purpura, Thrombocytopenic, Idiopathic, Liver Diseases, Thrombocytopenia
NCT Number
NCT02389621
NCT01129024
NCT01054443
NCT03897413
Intervention Type
Drug
Drug
Drug
Drug, Dietary Supplement
Indications
Chronic Liver Disease; Thrombocytopenia
Immune Thrombocytopenia
Healthy Volunteer
Study Phase
Phase 3
Phase 2
Phase 2
Phase 1
Recruitment Status
Completed
Terminated
Terminated
Completed
Recombinant human thrombopoietin
rhTPO (3SBio)
Approved
Shenyang Sunshine Pharmaceutical Co Ltd
Purpura, Thrombocytopenic, Idiopathic, Liver Cirrhosis, Thrombocytopenia
NCT Number
NCT03633019
NCT02267993
NCT03119974
NCT01379391
NCT02487563
NCT03492515
NCT02391272
NCT02244658
NCT02270801
NCT02139501
NCT01506414
NCT02203422
NCT01805648
NCT02707497
NCT01319669
NCT02094248
NCT02857530
NCT00006225
NCT00003597
NCT03673215
NCT02572596
NCT02344979
NCT00038012
Intervention Type
Drug
Drug
Drug
Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Procedure, Biological
Biological, Drug
Drug
Drug
Procedure, Drug
Indications
Thrombocytopenia
Thrombocytopenia
Persistent or Chronic ITP
Allogeneic Hematopoietic Stem Cell Transplantation; Myeloablative; Delayed Platelet Engraftment
Thrombocytopenia; Hematologic Diseases
Immune Thrombocytopenia
Immune Thrombocytopenia; Pregnancy
Antineoplastic Adverse Reaction; Thrombocytopenia; Acute Myelocytic Leukemia
Immune Thrombocytopenia; Pregnancy
Immune Thrombocytopenia
Purpura; Idiopathic Thrombocytopenic Purpura
Immune Thrombocytopenia
Thrombocytopenia; Immune Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Sepsis; Thrombocytopenia
Carcinoma, Non-Small-Cell Lung
Sepsis; Thrombocytopenia
Anemia, Aplastic
Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic/Myeloproliferative Diseases
Cancer
Liver Cirrhosis
Multiple Myeloma
Thrombocytopenia
Neoplasms, Gynecologic
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 1/Phase 2
Phase 1
Early Phase 1
N/A
N/A
N/A
Recruitment Status
Recruiting
Completed
Recruiting
Unknown status
Completed
Not yet recruiting
Completed
Unknown status
Unknown status
Completed
Completed
Withdrawn
Unknown status
Recruiting
Terminated
Unknown status
Unknown status
Completed
Completed
Recruiting
Unknown status
Unknown status
Completed
Eltrombopag Diolamine
SB-497115-GR, ETB-115, SB-497115
Approved
Glaxosmithkline Plc
Purpura, Thrombocytopenic, Idiopathic, HIV Infections, Leukemia, Non-alcoholic Fatty Liver Disease, Purpura, Myelodysplastic Syndromes, Liver Cirrhosis, Liver Diseases, Delayed Graft Function, Anemia, Aplastic, Hepatitis B, Hepatitis C, Thrombocytopenia, Hepatitis C, Chronic
NCT Number
NCT01957176
NCT04518475
NCT03243656
NCT01055600
NCT04102033
NCT03896971
NCT03844360
NCT00888901
NCT03771378
NCT01098487
NCT03119974
NCT03413306
NCT00516321
NCT00529568
NCT02877212
NCT02093325
NCT01621204
NCT00351468
NCT03939637
NCT02099747
NCT00996216
NCT01520909
NCT00828750
NCT00678587
NCT00370331
NCT01762761
NCT02158936
NCT01433978
NCT00540423
NCT02201290
NCT03515096
NCT01821625
NCT01428635
NCT03701217
NCT02773225
NCT03025698
NCT01484314
NCT02404025
NCT02422394
NCT03524612
NCT04516837
NCT01757145
NCT00424177
NCT03754634
NCT01488565
NCT01440374
NCT00110799
NCT02148133
NCT01328587
NCT01147809
NCT02912208
NCT00902018
NCT04600960
NCT01940562
NCT01893372
NCT01652599
NCT00102726
NCT00961064
NCT02402998
NCT01891994
NCT01703169
NCT01880047
NCT01500538
NCT04346654
NCT02010645
NCT01168921
NCT02998645
NCT01000051
NCT03206086
NCT00908037
NCT01927731
NCT02928419
NCT00102739
NCT03988608
NCT01636778
NCT01890746
NCT03664518
NCT01791101
NCT00909363
NCT01194167
NCT02446145
NCT01610180
NCT00861601
NCT03948529
NCT03718533
NCT01772420
NCT03638817
NCT04328727
NCT00922883
NCT03603795
NCT01133860
NCT02834286
NCT04371939
NCT03830749
NCT04797000
NCT04304820
NCT02071901
NCT01623167
NCT04269889
NCT01286038
NCT02323178
NCT01656252
NCT01113502
NCT01397149
NCT00359463
NCT04542382
NCT01491594
NCT01072162
NCT01550185
NCT00903422
NCT00688272
NCT04485416
NCT02281370
NCT02254434
NCT00487968
NCT01481220
NCT00442871
NCT01657552
NCT00903929
NCT04518878
NCT00833378
NCT00358540
NCT01286675
NCT01971684
NCT01618734
NCT01974232
NCT01235988
NCT01416311
NCT01443351
NCT01064336
NCT01715779
NCT02298075
NCT01864512
NCT01458080
NCT01386723
NCT02063763
NCT03412188
NCT01439321
NCT03902041
NCT00643929
NCT04214951
NCT01236014
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other, Drug
Drug
Drug
Other, Drug
Other, Drug
Other, Drug
Drug
Drug
Drug
Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other, Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Diagnostic Test, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Procedure, Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Indications
Thrombocytopaenia
Primary Immune Thrombocytopenia (ITP)
Eltrombopag
Thrombocytopaenia
Immune Thrombocytopenia
Aplastic Anemia
Hematological Neoplasms
Idiopathic Thrombocytopenic Purpura
Primary Immune Thrombocytopenia
Purpura, Thrombocytopaenic, Idiopathic
Persistent or Chronic ITP
Acquired Aplastic Anemia
Hepatitis C, Chronic
Hepatitis C, Chronic
Immune Thrombocytopenic Purpura (ITP)
Solid Tumor
Immune Thrombocytopenic Purpura
Purpura, Thrombocytopaenic, Idiopathic
Immune Thrombocytopenia
Severe Aplastic Anemia
Hepatitis C
Idiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Idiopathic
Non-alcoholic Steatohepatitis; Chronic Liver Disease; HCV; NASH - Nonalcoholic Steatohepatitis; HIV Infection; Thrombocytopenia; Hepatitis C Virus; HBV; Human Immunodeficiency Virus; Liver Diseases; Hepatitis B Virus
Purpura, Thrombocytopaenic, Idiopathic
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Thrombocytopaenia
Idiopathic Thrombocytopenic Purpura
Chronic Idiopathic Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Idiopathic
Purpura, Thrombocytopenic, Idiopathic
Eltrombopag; Hematopoietic Stem Cell Transplantation; Thrombocytopenia
Thrombocytopenia; Hepatitis C
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Primary Myelofibrosis; Thrombocytopenia
Eltrombopag; Thrombocytopenia; Acute Myeloid Leukemia
Anemia, Aplastic
Aplastic Anemia
Thrombocytopenia; Multiple Myeloma
Aplastic Anemia
Inherited Platelet Disorder
Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenia
Hematological Malignancy; Bone Marrow Failure Syndrome
Purpura, Thrombocytopaenic, Idiopathic
Thrombocytopenia
Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)
Thrombocytopaenia
Hepatitis C, Chronic; Hepatitis C; Thrombocytopenia
Cytopaenia
Moderate Aplastic Anemia; Unilineage Bone Marrow Failure Disorders
Thrombocytopaenia
Myelodysplastic Syndromes; Thrombocytopenia
Immune Thrombocytopenia
Chemotherapy-induced Thrombocytopenia; Eltrombopag
Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.
Leukemia
Immune Thrombocytopenic Purpura
Thrombocytopaenia
Myelodysplastic Syndromes; Thrombocytopenia
Primacy Immune Thrombocytopenia
Severe Aplastic Anemia (SAA)
Severe Aplastic Anemia; Very Severe Aplastic Anemia; Moderate Aplastic Anemia
Immune Thrombocytopenia; Platelet Disorder
Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Immune Thrombocytopenia (ITP)
Leukemia
CLL; Leukemia
Severe Aplastic Anemia
Thrombocytopenia
Fanconi's Anemia
Purpura, Thrombocytopaenic, Idiopathic
Bone Marrow Transplantation Recipient; Cord Blood Transplant Recipient; Hematopoietic Cell Transplantation Recipient
Myelodysplastic Syndromes
Purpura, Thrombocytopaenic, Idiopathic
Hepatitis C, Chronic
Acute Leukaemia
Thrombocytopenia Purpura; Chronic HBV Infection
Thrombocytopenia
Wiskott-Aldrich Syndrome; Thrombocytopenia; Bleeding
Thrombocytopenia
Acute Myeloid Leukemia
Purpura, Thrombocytopenic, Idiopathic; Autoimmune Thrombocytopenic Purpura; Autoimmune Thrombocytopenia; Chronic Lymphocytic Leukemia; Non Hodgkin's Lymphoma
Liver Diseases
Leukemia; Graft Failure
Poor Graft Function
Adult Myelodysplastic Syndrome; Anemia; Chronic Myelomonocytic Leukemia
Thrombocytopenia
Severe Aplastic Anemia (SAA)
Anemia, Aplastic; Anemia, Hypoplastic; Thrombocytopenia
Acute Myeloid Leukemia
Blood Platelet Disorders
Immune Thrombocytopenia
Wiskott-Aldrich Syndrome
Immune Thrombocytopenia
Myelodysplastic Syndromes
Severe Aplastic Anemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia
Severe Aplastic Anemia
Anemia, Diamond-Blackfan
Myelodysplastic Syndrome (MDS); Thrombocytopenia
CMML; Thrombocytopenia
Acute Myeloid Leukemia
Male and Female Subjects, Greater Than 60 Years of Age With Non-M3 AML
Chronic Lymphocytic Leukemia; Thrombocytopenia
Purpura, Thrombocytopaenic, Idiopathic
Healthy Volunteers
Sarcoma, Soft Tissue; Osteosarcoma; Neoplasms, Connective and Soft Tissue
Purpura, Thrombocytopaenic, Idiopathic
Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Myelodysplastic Syndrome
Purpura, Thrombocytopaenic, Idiopathic
Solid Tumor, Childhood; Solid Tumor
Purpura, Thrombocytopenic, Idiopathic
Cirrhosis, Liver
Healthy Subjects; Purpura, Thrombocytopenic, Idiopathic
Myelodysplastic Syndrome; Thrombocytopenia
Purpura, Thrombocytopaenic, Idiopathic
Thrombocytopaenia
Thrombocytopenia; Acute Radiation Syndrome
Immune Thrombocytopenia
Hepatitis C
Thrombocytopaenia
Multiple Myeloma
Immune Thrombocytopenia
Immune Thrombocytopenia; Thrombopoietin Receptor Agonist
Immune Thrombocytopenia
Thrombocytopaenia
Purpura, Thrombocytopaenic, Idiopathic
Idiopathic Thrombocytopenic Purpura
Purpura, Thrombocytopaenic, Idiopathic
Hepatitis C
Immune Thrombocytopenia
Immune Thrombocytopenia
Hepatitis C
Immune Thrombocytopenia
Adult Patients; Immune Primary Thrombocytopenia; Splenectomy; TPO-mimetics
Idiopathic Thrombocytopenic Purpura
Immune Thrombocytopenic Purpura
Allogeneic Hematopoietic Stem Cell Transplantation; Eltrombopag
Purpura, Thrombocytopaenic, Idiopathic
Corticosteroid-resistant or Relapsed ITP
Thrombocytopaenia
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Active, not recruiting
Recruiting
Recruiting
Withdrawn
Not yet recruiting
Recruiting
Recruiting
Completed
Recruiting
Completed
Recruiting
Recruiting
Completed
Completed
Unknown status
Unknown status
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Terminated
Terminated
Completed
Completed
Recruiting
Terminated
Active, not recruiting
Recruiting
Recruiting
Recruiting
Terminated
Completed
Completed
Active, not recruiting
Recruiting
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Completed
Recruiting
Completed
Recruiting
Unknown status
Completed
Completed
Completed
Active, not recruiting
Unknown status
Active, not recruiting
Completed
Completed
Terminated
Recruiting
Terminated
Active, not recruiting
Active, not recruiting
Completed
Recruiting
Completed
Active, not recruiting
Terminated
Completed
Active, not recruiting
Completed
Completed
Recruiting
Active, not recruiting
Terminated
Withdrawn
Unknown status
Completed
Completed
Recruiting
Completed
Completed
Recruiting
Recruiting
Completed
Recruiting
Completed
Unknown status
Recruiting
Suspended
Not yet recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Terminated
Terminated
Terminated
Completed
Not yet recruiting
Terminated
Completed
Terminated
Completed
Completed
Not yet recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Withdrawn
Completed
Completed
Recruiting
Withdrawn
Completed
Terminated
Completed
Recruiting
Completed
Not yet recruiting
Completed
Active, not recruiting
Completed
Romiplostim
AMP-2, AMG-531
Approved
Amgen Inc
Purpura, Thrombocytopenic, Idiopathic, Solid tumours, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hodgkin Disease, Anemia, Aplastic, Acute Radiation Syndrome, Lung Neoplasms, Thrombocytopenia, Purpura, Thrombocytopenic, Lymphoma, Non-Hodgkin, Carcinoma, Non-Small-Cell Lung
NCT Number
NCT00907478
NCT02760251
NCT00508820
NCT02279173
NCT00603642
NCT02868099
NCT00415532
NCT01071954
NCT01444417
NCT03362177
NCT00116688
NCT00102323
NCT03343847
NCT03937154
NCT00102336
NCT04095936
NCT00440037
NCT02773290
NCT03957694
NCT00413283
NCT04588194
NCT02094417
NCT02338414
NCT03622931
NCT01516619
NCT00902018
NCT00321711
NCT04478123
NCT02227576
NCT04673266
NCT01143038
NCT01153919
NCT00303472
NCT00305435
NCT00614523
NCT04371939
NCT00111475
NCT04289207
NCT04671901
NCT01676961
NCT02052882
NCT01980030
NCT00147225
NCT00283439
NCT02868060
NCT00117143
NCT00299182
NCT02046291
NCT04478227
NCT01439321
NCT04350164
NCT01971684
NCT02298075
NCT01236014
Intervention Type
Biological
Drug
Biological
Drug
Drug
Drug
Biological, Drug
Biological
Drug
Other, Biological
Biological
Biological, Drug
Other, Biological
Drug
Biological, Drug
Drug
Biological
Biological
Drug
Biological, Drug
Drug
Drug
Drug
Drug
Drug
Other, Drug
Biological, Drug
Drug
Drug
Drug
Biological
Other, Biological, Drug
Drug
Drug
Biological, Drug
Drug
Drug
Drug
Drug
Biological
Biological
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Indications
Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Immune Thrombocytopenia
Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura
Immune Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Immune Thrombocytopenia
Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura; Immune Thrombocytopenia
Chemotherapy-induced Thrombocytopenia
Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Chemotherapy-induced Thrombocytopenia
Chemotherapy-induced Thrombocytopenia
Thrombocytopenia; Idiopathic Thrombocytopenic Purpura
Aplastic Anemia
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Aplastic Anemia
Aplastic Anemia
Lung Cancer; Chemotherapy-Induced Thrombocytopenia; Non-Small Cell Lung Cancer; Cancer; Lung Neoplasms; Oncology; Solid Tumors; Thrombocytopenia
Immune Thrombocytopenia; Thrombotic Thrombocytopenic Purpura
Aplastic Anemia
Immune Thrombocytopenia
Ovarian Cancer
Non-Hodgkin Lymphoma
Immune Thrombocytopenia
MDS; Myelodysplastic Syndromes; Thrombocytopenia
Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; HDT-AHCT
Thrombocytopenia; Glioblastoma
Lymphoma Patients; Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Hepatitis C Infection; Thrombocytopenia
Thrombocytopenia; MDS; Myelodysplastic Syndromes; Refractory Cytopenias
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
MDS; Myelodysplastic Syndromes; Thrombocytopenia
Wiskott-Aldrich Syndrome
Idiopathic Thrombocytopenic Purpura
Immune Thrombocytopenia
Solid Tumor; Solid Tumor, Childhood; Solid Carcinoma
Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma; Thrombocytopenia
Isolated Chemotherapy-induced Thrombocytopenia
Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Solid Tumors; Advanced Cancer
Chemotherapy-Induced Thrombocytopenia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Cancer; Oncology; Thrombocytopenia
Immune Thrombocytopenia (ITP)
Thrombocytopenic Purpura
Lymphoma
Hematologic Malignancies
Bone Marrow Failure Disorders; Aplastic Anemia; Thrombocytopenia; Refractory Cytopenia of Childhood; Myelodysplastic Syndrome(MDS)
Immune Thrombocytopenic Purpura
Wiskott-Aldrich Syndrome
Immune Thrombocytopenia
Immune Thrombocytopenia
Thrombocytopaenia
Study Phase
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Withdrawn
Recruiting
Completed
Recruiting
Completed
Active, not recruiting
Active, not recruiting
Completed
Recruiting
Completed
Unknown status
Terminated
Unknown status
Completed
Completed
Recruiting
Terminated
Recruiting
Completed
Terminated
Completed
Completed
Completed
Recruiting
Completed
Not yet recruiting
Recruiting
Terminated
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Recruiting
Completed
Completed
Completed
Recruiting
Completed
Avatrombopag Maleate
E-5501, YM-477, AKR-501, AS-1670542, AKR-501-monomaleate
Approved
Astellas Pharma Inc
Purpura, Thrombocytopenic, Idiopathic, Liver Diseases, Cardiovascular Diseases, Thrombocytopenia
NCT Number
NCT04638829
NCT01976104
NCT03471078
NCT04516967
NCT01972529
NCT01438840
NCT01433978
NCT03326843
NCT04728789
NCT02227693
NCT00441090
NCT00914927
NCT04437953
NCT04312789
NCT01355289
NCT00625443
NCT01327872
NCT01549054
NCT01289509
NCT02809768
NCT01437384
NCT02039076
NCT01251731
NCT01759394
NCT01260155
NCT01774773
NCT04609891
NCT03554759
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Immune Thrombocytopenia
Thrombocytopenia Associated With Liver Disease
Chemotherapy-induced Thrombocytopenia
Immune Thrombocytopenia
Thrombocytopenia Associated With Liver Disease
Chronic Thrombocytopenia; Immune Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Thrombocytopenia
Aplastic Anemia; Drug Effect
Thrombocytopenia Associated With Chronic Liver Disease
Chronic Idiopathic Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenia Related to Chronic Liver Disease
Thrombocytopenia; Cancer; Liver Diseases
Platelet Disorder
Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Idiopathic; Acute Idiopathic Thrombocytopenic Purpura; Chronic Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Idiopathic Thrombocytopenia Purpura
Healthy Participants
Idiopathic Thrombocytopenic Purpura (ITP)
Thrombocytopenia
Healthy Subjects
Healthy Volunteers
Healthy Subjects
Healthy
Thrombocytopenia
Thrombocytopenia
Study Phase
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Recruiting
Completed
Active, not recruiting
Recruiting
Completed
Completed
Terminated
Terminated
Not yet recruiting
Completed
Completed
Completed
Withdrawn
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Terminated
Recombinant human thrombopoietin biosimilar (Biolotus)
Approved
Biolotus
Thrombocytopenia
Herombopag Olamine
SHR-8735
NDA/BLA
Jiangsu Hengrui Medicine Co Ltd
Purpura, Thrombocytopenic, Idiopathic, Anemia, Aplastic, Thrombocytopenia
NCT Number
NCT04737850
NCT03222843
NCT03825744
NCT03976882
NCT03557099
NCT02403440
NCT03977805
NCT04701216
NCT03603132
NCT04688008
NCT02614846
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Immune Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Severe Aplastic Anemia
Chemotherapy-Induced Thrombocytopenia
Severe Aplastic Anemia
Purpura, Thrombocytopenic, Idiopathic
Healthy
Healthy Volunteers
Immune Thrombocytopenia
Bioavailability Study
Chronic Idiopathic Thrombocytopenic Purpura
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Recruitment Status
Not yet recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Unknown status
Completed
Not yet recruiting
Completed
Completed
Unknown status
Romiplostim biosimilar (Intas Pharmaceuticals)
Phase 3 Clinical
Intas Biopharmaceuticals
Purpura, Thrombocytopenic, Idiopathic
Romiplostim biosimilar (Enzene Biosciences)
267639-76-9
Phase 3 Clinical
Enzene Biosciences
Purpura, Thrombocytopenic, Idiopathic
Recombinant human thrombopoietin mimetic-fusion protein (Qilu Pharmaceutical)
QL-0911
Phase 3 Clinical
Qilu Pharmaceutical Co Ltd
Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia
Pegylated thrombopoietin mimetic peptide
SF-303, PEG-TPOm, RWJ-800088, JNJ-26366821
Phase 2 Clinical
Johnson & Johnson
Anemia, Thrombocytopenia
NCT Number
NCT03990519
Intervention Type
Drug
Indications
Healthy
Study Phase
Phase 1
Recruitment Status
Completed
Recombinant human thrombopoietin (CPGJ)
Phase 1 Clinical
Shanghai Cp Guojian Pharmaceutical Co Ltd
Thrombocytopenia
Recombinant human thrombopoietin mimetics (Shandong Quangang)
Phase 1 Clinical
Shandong Quangang Pharmaceutical Co Ltd
Purpura, Thrombocytopenic, Idiopathic
NIP-022
NIP-022, ONO-7746, YHI-1501
Phase 1 Clinical
Nissan Chemical
Thrombocytopenia
NCT Number
NCT00956371
NCT01106664
NCT01345214
Intervention Type
Drug
Drug
Drug
Indications
Healthy Adult Subjects
Healthy Adult Subjects
Chemotherapy-Induced Thrombocytopenia
Study Phase
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Terminated
Thrombopoietin agonist (Scripps Research)
3D9
Clinical
The Scripps Research Institute
Thrombocytopenia
SCB-219
SCB-219
Preclinical
Sichuan Sanyecao Bio-Pharmaceutical Co Ltd
Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia
Totrombopag Choline
SB-559448, SB-559448-AAA
Pending
Ligand Pharmaceuticals Inc
Thrombocytopenia
BVI-007
BVI-007
Pending
Biovascular
Myocardial Infarction, Stroke
Butyzamide
Pending
Shionogi & Co Ltd
Thrombocytopenia
Thrombopoietin (Genentech)
Discontinued
Genentech Inc
Hodgkin Disease, Multiple Myeloma, Sarcoma, Thrombocytopenia, Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT00039910
NCT00038311
NCT00037791
NCT00187109
NCT00003597
Intervention Type
Drug
Drug
Drug
Drug
Biological, Drug
Indications
Non-Hodgkin Lymphoma; Hodgkin Disease; Thrombocytopenia
Sarcoma
Neoplasms; Thrombocytopenia; Multiple Myeloma; Lymphoma, Malignant
Germ Cell Tumors; Hepatic Cancer; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma
Cancer
Study Phase
Phase 3
Phase 3
Phase 3
Phase 1/Phase 2
Phase 1
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Pegacaristim
KRN-9000
Discontinued
Kirin, Zymogenetics, Amgen Inc
Drug-Related Side Effects and Adverse Reactions, Thrombocytopenia
Promegapoietin
PMP
Discontinued
Pfizer Pharmaceuticals Ltd (China)
Thrombocytopenia
SC-71858
SC-71858
Discontinued
Pharmacia & Upjohn
Thrombocytopenia
References
Title
Authors
Source
The DNA sequence and biological annotation of human chromosome 1
Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., Bentley D.R.,
Nature 441:315-321(2006)
Ubiquitination and degradation of the thrombopoietin receptor c-Mpl
Saur S.J., Sangkhae V., Geddis A.E., Kaushansky K., Hitchcock I.S.,
Blood 115:1254-1263(2010)
Characterization of single-nucleotide polymorphisms in coding regions of human genes
Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.,
Nat. Genet. 22:231-238(1999)
Cloning and characterization of a family of proteins associated with Mpl
Meunier C.F., Bordereaux D., Porteu F., Gisselbrecht S., Chretien S., Courtois G.,
J. Biol. Chem. 277:9139-9147(2002)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., Tsuboi K., Nitta M., Miyazaki H., Iida S., Ueda R.,
Blood 103:4198-4200(2004)
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis
Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., Salvatori R., Ingersoll R.G., Spivak J.L.,
Proc. Natl. Acad. Sci. U.S.A. 101:11444-11447(2004)
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., McClure R.F., Litzow M.R., Gilliland D.G., Tefferi A.,
Blood 108:3472-3476(2006)
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease
Germeshausen M., Ballmaier M., Welte K.,
Hum. Mutat. 27:296-296(2006)
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., Levine R.L.,
PLoS Med. 3:E270-E270(2006)
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity
Ding J., Komatsu H., Iida S., Yano H., Kusumoto S., Inagaki A., Mori F., Ri M., Ito A., Wakita A., Ishida T., Nitta M., Ueda R.,
Blood 114:3325-3328(2009)
MPL W515L mutation in pediatric essential thrombocythemia
Farruggia P., D'Angelo P., La Rosa M., Scibetta N., Santangelo G., Lo Bello A., Duner E., Randi M.L., Putti M.C., Santoro A.,
Pediatr. Blood Cancer 60:E52-E54(2013)
The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis
Stockklausner C., Klotter A.C., Dickemann N., Kuhlee I.N., Duffert C.M., Kerber C., Gehring N.H., Kulozik A.E.,
Blood 125:1159-1169(2015)
Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily
Vigon I., Mornon J.-P., Cocault L., Mitjavila M.-T., Tambourin P., Gisselbrecht S., Souyri M.,
Proc. Natl. Acad. Sci. U.S.A. 89:5640-5644(1992)
Structure and transcription of the human c-mpl gene (MPL)
Mignotte V., Vigon I., Boucher de Crevecoeur E., Romeo P.-H., Lemarchandel V., Chretien S.,
Genomics 20:5-12(1994)
Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.
Vigon I., Mornon J.-P., Cocault L., Mitjavila M.-T., Tambourin P., Gisselbrecht S., Souyri M.,
Proc. Natl. Acad. Sci. U.S.A. 89:5640-5644(1992)
Structure and transcription of the human c-mpl gene (MPL).
Mignotte V., Vigon I., Boucher de Crevecoeur E., Romeo P.-H., Lemarchandel V., Chretien S.,
Genomics 20:5-12(1994)
The DNA sequence and biological annotation of human chromosome 1.
Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., Bentley D.R.,
Nature 441:315-321(2006)
Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.
Saur S.J., Sangkhae V., Geddis A.E., Kaushansky K., Hitchcock I.S.,
Blood 115:1254-1263(2010)
Characterization of single-nucleotide polymorphisms in coding regions of human genes.
Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.,
Nat. Genet. 22:231-238(1999)
Cloning and characterization of a family of proteins associated with Mpl.
Meunier C.F., Bordereaux D., Porteu F., Gisselbrecht S., Chretien S., Courtois G.,
J. Biol. Chem. 277:9139-9147(2002)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.
Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., Tsuboi K., Nitta M., Miyazaki H., Iida S., Ueda R.,
Blood 103:4198-4200(2004)
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.
Moliterno A.R., Williams D.M., Gutierrez-Alamillo L.I., Salvatori R., Ingersoll R.G., Spivak J.L.,
Proc. Natl. Acad. Sci. U.S.A. 101:11444-11447(2004)
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., McClure R.F., Litzow M.R., Gilliland D.G., Tefferi A.,
Blood 108:3472-3476(2006)
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease.
Germeshausen M., Ballmaier M., Welte K.,
Hum. Mutat. 27:296-296(2006)
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., Levine R.L.,
PLoS Med. 3:E270-E270(2006)
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity.
Ding J., Komatsu H., Iida S., Yano H., Kusumoto S., Inagaki A., Mori F., Ri M., Ito A., Wakita A., Ishida T., Nitta M., Ueda R.,
Blood 114:3325-3328(2009)
MPL W515L mutation in pediatric essential thrombocythemia.
Farruggia P., D'Angelo P., La Rosa M., Scibetta N., Santangelo G., Lo Bello A., Duner E., Randi M.L., Putti M.C., Santoro A.,
Pediatr. Blood Cancer 60:E52-E54(2013)
The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.
Stockklausner C., Klotter A.C., Dickemann N., Kuhlee I.N., Duffert C.M., Kerber C., Gehring N.H., Kulozik A.E.,
Blood 125:1159-1169(2015)
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo.
Scheding S., Bergmann M., Shimosaka A., Wolff P., Driessen C., Rathke G., Jaschonek K., Brugger W., Kanz L.,
Transfusion 42:321-327(2002)
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia.
Mesa R.A., Hanson C.A., Li C.Y., Yoon S.Y., Rajkumar S.V., Schroeder G., Tefferi A.,
Blood 99:4131-4137(2002)
The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia.
Teofili L., Pierconti F., Di Febo A., Maggiano N., Vianelli N., Ascani S., Rossi E., Pileri S., Leone G., Larocca L.M., De Stefano V.,
Blood 100:714-717(2002)
A novel MPL point mutation resulting in thrombopoietin-independent activation.
Abe M., Suzuki K., Inagaki O., Sassa S., Shikama H.,
Leukemia 16:1500-1506(2002)
The cytoplasmic domain of Mpl receptor transduces exclusive signals in embryonic and fetal hematopoietic cells.
Challier C., Cocault L., Berthier R., Binart N., Dusanter-Fourt I., Uzan G., Souyri M.,
Blood 100:2063-2070(2002)
Modulation of human c-mpl gene expression by thrombopoietin through protein kinase C.
Sunohara M., Morikawa S., Sato T., Sato I., Sato T., Fuse A.,
Cell Mol Biol (Noisy-le-grand) 49 Online Pub:OL393-8(2003)
A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation.
Coers J., Ranft C., Skoda R.C.,
J. Biol. Chem. 279:36397-36404(2004)
Association of single nucleotide polymorphisms in the thrombopoietin-receptor gene, but not the thrombopoietin gene, with differences in platelet count.
Zeng S.M., Murray J.C., Widness J.A., Strauss R.G., Yankowitz J.,
Am J Hematol 77:12-21(2004)
Targeting c-Mpl for revival of human immunodeficiency virus type 1-induced hematopoietic inhibition when CD34+ progenitor cells are re-engrafted into a fresh stromal microenvironment in vivo.
Koka P.S., Kitchen C.M., Reddy S.T.,
J Virol 78:11385-11392(2004)
Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression.
Nakayama H., Ihara K., Hikino S., Yamamoto J., Nagatomo T., Takemoto M., Hara T.,
J Mol Med (Berl) 83:316-320(2005)
Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.
Heller P.G., Glembotsky A.C., Gandhi M.J., Cummings C.L., Pirola C.J., Marta R.F., Kornblihtt L.I., Drachman J.G., Molinas F.C.,
Blood 105:4664-4670(2005)
Janus kinases affect thrombopoietin receptor cell surface localization and stability.
Royer Y., Staerk J., Costuleanu M., Courtoy P.J., Constantinescu S.N.,
J Biol Chem 280:27251-27261(2005)
Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels.
MPD Research Consortium, Goerttler P.L., Marz E., Johansson P.L., Andreasson B., Kutti J., Moliterno A.R., Marchioli R., Spivak J.L., Pahl H.L.,
Haematologica 90:851-853(2005)
A microtubule associated protein (hNUDC) binds to the extracellular domain of thrombopoietin receptor (Mpl).
Pan R.M., Yang Y., Wei M.X., Yu X.B., Ge Y.C., Xu P.,
J Cell Biochem 96:741-750(2005)
Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression.
Sundell I.B., Koka P.S.,
Curr HIV Res 4:107-116(2006)
The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms.
Tong W., Sulahian R., Gross A.W., Hendon N., Lodish H.F., Huang L.J.,
J Biol Chem 281:38930-38940(2006)
Lineage-specific expression of granulocyte colony-stimulating factor and thrombopoietin receptors in terminally differentiated hematopoietic cells.
Kuwaki T., Oda A., Yuki C., Suzuki H., Murasaki K., Fujita H., Miyazaki H., Ikeda Y.,
Exp Hematol 34:1651-1654(2006)
Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis.
Hu W.Y., Zhao Y., Ishii T., Sozer S., Shi J., Zhang W., Bruno E., Hoffman R., Xu M.,
Br J Haematol 137:378-379(2007)
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
MPD Research Consortium, Guglielmelli P., Pancrazzi A., Bergamaschi G., Rosti V., Villani L., Antonioli E., Bosi A., Barosi G., Vannucchi A.M.,
Br J Haematol 137:244-247(2007)
Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes.
Pardanani A., Lasho T.L., Finke C., Markovic S.N., Tefferi A.,
Leukemia 21:2206-2207(2007)
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
Pardanani A., Lasho T.L., Finke C., Mesa R.A., Hogan W.J., Ketterling R.P., Gilliland D.G., Tefferi A.,
Stem Cells 25:2358-2362(2007)
Regulation of cell differentiation by hNUDC via a Mpl-dependent mechanism in NIH 3T3 cells.
Zhang Y.P., Tang Y.S., Chen X.S., Xu P.,
Exp Cell Res 313:3210-3221(2007)
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations.
Savoia A., Dufour C., Locatelli F., Noris P., Ambaglio C., Rosti V., Zecca M., Ferrari S., di Bari F., Corcione A., Di Stazio M., Seri M., Balduini C.L.,
Haematologica 92:1186-1193(2007)
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
Chaligne R., James C., Tonetti C., Besancenot R., Le Couedic J.P., Fava F., Mazurier F., Godin I., Maloum K., Larbret F., Lecluse Y., Vainchenker W., Giraudier S.,
Blood 110:3735-3743(2007)
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams D.M., Kim A.H., Rogers O., Spivak J.L., Moliterno A.R.,
Exp Hematol 35:1641-1646(2007)
[Expressions of c-mpl proteins on CD34+ bone marrow cells and platelets of the patients with polycythemia vera].
Bai J., Shao Z.H., Shi J., Jia H.R., Sun J.,
Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:1061-1064(2007)
MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l.
Zipperer E., Wulfert M., Germing U., Haas R., Gattermann N.,
Ann Hematol 87:413-415(2008)
Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl.
Abdel-Azim H., Zhu Y., Hollis R., Wang X., Ge S., Hao Q.L., Smbatyan G., Kohn D.B., Rosol M., Crooks G.M.,
Blood 111:4064-4074(2008)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.
Kiladjian J.J., Cervantes F., Leebeek F.W., Marzac C., Cassinat B., Chevret S., Cazals-Hatem D., Plessier A., Garcia-Pagan J.C., Darwish Murad S., Raffa S., Janssen H.L., Gardin C., Cereja S., Tonetti C., Giraudier S., Condat B., Casadevall N., Fenaux P., Valla D.C.,
Blood 111:4922-4929(2008)
Promoter regulatory motifs involved in c-mpl gene expression induced by PMA.
Sunohara M., Morikawa S., Sato T., Miyado M., Sato I., Sato T., Fuse A.,
Cell Biol Int 32:692-697(2008)
JAK and MPL mutations in myeloid malignancies.
Tefferi A.,
Leuk Lymphoma 49:388-397(2008)
Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia.
Tijssen M.R., di Summa F., van den Oudenrijn S., Zwaginga J.J., van der Schoot C.E., Voermans C., de Haas M.,
Br J Haematol 141:808-813(2008)
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., Wilkins B.S., Reilly J.T., Hasselbalch H.C., Bowman R., Wheatley K., Buck G., Harrison C.N., Green A.R.,
Blood 112:141-149(2008)
MPL W515L mutation in Chinese patients with myeloproliferative diseases.
Xu W., Li J.Y., Xia J., Zhang S.J., Fan L., Qiao C.,
Leuk Lymphoma 49:955-958(2008)
YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.
Hitchcock I.S., Chen M.M., King J.R., Kaushansky K.,
Blood 112:2222-2231(2008)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.
Vannucchi A.M., Antonioli E., Guglielmelli P., Pancrazzi A., Guerini V., Barosi G., Ruggeri M., Specchia G., Lo-Coco F., Delaini F., Villani L., Finotto S., Ammatuna E., Alterini R., Carrai V., Capaccioli G., Di Lollo S., Liso V., Barbui T.,
Blood 112:844-847(2008)
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.
Chaligne R., Tonetti C., Besancenot R., Roy L., Marty C., Mossuz P., Kiladjian J.J., Socie G., Bordessoule D., Le Bousse-Kerdiles M.C., Vainchenker W., Giraudier S.,
Leukemia 22:1557-1566(2008)
JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P., Levine R.L.,
Acta Haematol 119:218-225(2008)
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
Pancrazzi A., Guglielmelli P., Ponziani V., Bergamaschi G., Bosi A., Barosi G., Vannucchi A.M.,
J Mol Diagn 10:435-441(2008)
AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells.
Satoh Y., Matsumura I., Tanaka H., Ezoe S., Fukushima K., Tokunaga M., Yasumi M., Shibayama H., Mizuki M., Era T., Okuda T., Kanakura Y.,
J Biol Chem 283:30045-30056(2008)
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Schnittger S., Bacher U., Haferlach C., Beelen D., Bojko P., Burkle D., Dengler R., Distelrath A., Eckart M., Eckert R., Fries S., Knoblich J., Kochling G., Laubenstein H.P., Petrides P., Planker M., Pihusch R., Weide R., Kern W., Haferlach T.,
Haematologica 94:141-144(2009)
Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene.
El-Harith e.l.-H.A., Roesl C., Ballmaier M., Germeshausen M., Frye-Boukhriss H., von Neuhoff N., Becker C., Nurnberg G., Nurnberg P., Ahmed M.A., Hubener J., Schmidtke J., Welte K., Stuhrmann M.,
Br J Haematol 144:185-194(2009)
Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia.
Ayala R.M., Martinez-Lopez J., Albizua E., Diez A., Gilsanz F.,
Am J Hematol 84:79-86(2009)
[MPLW515L point mutation in patients with myeloproliferative disease].
Xia J., Xu W., Zhang S.J., Fan L., Qiao C., Li J.Y.,
Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:1421-1424(2008)
[Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z., Zhang R., Shen Y.M., Fei H.R., Zhu Z.L., Cen J.N.,
Zhonghua Xue Ye Xue Za Zhi 29:611-614(2008)
MPLW515L mutation in acute megakaryoblastic leukaemia.
Hussein K., Bock O., Theophile K., Schulz-Bischof K., Porwit A., Schlue J., Jonigk D., Kreipe H.,
Leukemia 23:852-855(2009)
Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.
Hussein K., Bock O., Theophile K., Schlue J., Ballmaier M., Kroger N., Gohring G., Busche G., Kreipe H.,
Blood 113:1391-1392(2009)
Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.
Marty C., Chaligne R., Lacout C., Constantinescu S.N., Vainchenker W., Villeval J.L.,
J Biol Chem 284:11781-11791(2009)
MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.
Ruan G.R., Jiang B., Li L.D., Niu J.H., Li J.L., Xie M., Qin Y.Z., Liu Y.R., Huang X.J., Chen S.S.,
Hematol Oncol 28:33-39(2010)
Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature.
Fox N.E., Chen R., Hitchcock I., Keates-Baleeiro J., Frangoul H., Geddis A.E.,
Exp Hematol 37:495-503(2009)
CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells.
Yamazaki H., Nishida H., Iwata S., Dang N.H., Morimoto C.,
Biochem Biophys Res Commun 383:172-177(2009)
Genetic mutations associated with cigarette smoking in pancreatic cancer.
Blackford A., Parmigiani G., Kensler T.W., Wolfgang C., Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Eshleman J.R., Goggins M., Jaffee E.M., Iacobuzio-Donahue C.A., Maitra A., Klein A., Cameron J.L., Olino K., Schulick R., Hruban R.H.,
Cancer Res 69:3681-3688(2009)
Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
Bojko P., Abenhardt W., Schnittger S., Haferlach T.,
Onkologie 32:191-195(2009)
Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome.
Vasikova A., Budinska E., Belickova M., Cermak J., Bruchova H.,
Neoplasma 56:335-342(2009)
Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S., Conneally E., Langabeer S.E.,
Acta Haematol 121:221-222(2009)
Interference RNA (RNAi)-based silencing of endogenous thrombopoietin receptor (Mpl) in Dami cells resulted in decreased hNUDC-mediated megakaryocyte proliferation and differentiation.
Pang S.F., Li X.K., Zhang Q., Yang F., Xu P.,
Exp Cell Res 315:3563-3573(2009)
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia.
Liu K., Martini M., Rocca B., Amos C.I., Teofili L., Giona F., Ding J., Komatsu H., Larocca L.M., Skoda R.C.,
Haematologica 94:1368-1374(2009)
JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A., Bieniaszewska M., Hellmann A., Limon J.,
Leuk Res 34:387-389(2010)
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.
Teofili L., Giona F., Torti L., Cenci T., Ricerca B.M., Rumi C., Nunes V., Foa R., Leone G., Martini M., Larocca L.M.,
Haematologica 95:65-70(2010)
Two rare MPL gene mutations in patients with essential thrombocythemia.
Ohashi H., Arita K., Fukami S., Oguri K., Nagai H., Yokozawa T., Hotta T., Hanada S.,
Int J Hematol 90:431-432(2009)
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
Pecquet C., Staerk J., Chaligne R., Goss V., Lee K.A., Zhang X., Rush J., Van Hees J., Poirel H.A., Scheiff J.M., Vainchenker W., Giraudier S., Polakiewicz R.D., Constantinescu S.N.,
Blood 115:1037-1048(2010)
MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.
Patnaik M.M., Lasho T.L., Finke C.M., Gangat N., Caramazza D., Siragusa S., Hanson C.A., Pardanani A., Tefferi A.,
Leukemia 24:859-860(2010)
Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky A.C., Korin L., Lev P.R., Chazarreta C.D., Marta R.F., Molinas F.C., Heller P.G.,
Eur J Haematol 84:398-405(2010)
Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Millecker L., Lennon P.A., Verstovsek S., Barkoh B., Galbincea J., Hu P., Chen S.S., Jones D.,
Cancer Genet Cytogenet 197:1-7(2010)
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.
Boyd E.M., Bench A.J., Goday-Fernandez A., Anand S., Vaghela K.J., Beer P., Scott M.A., Bareford D., Green A.R., Huntly B., Erber W.N.,
Br J Haematol 149:250-257(2010)
Modulation mechanism of c-Mpl promoter activity in megakaryoblastic cells.
Sunohara M., Morikawa S., Murata H., Fuse A., Sato I.,
Okajimas Folia Anat Jpn 86:89-91(2009)
Rescue of multi-lineage hematopoiesis during HIV-1 infection by human c-mpl gene transfer and reconstitution of CD34+ progenitor cells in vivo.
Zhang M., Poh T.Y., Louache F., Sundell I.B., Yuan J., Evans S., Koka P.S.,
J Stem Cells 4:161-177(2009)
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.
Jones A.V., Campbell P.J., Beer P.A., Schnittger S., Vannucchi A.M., Zoi K., Percy M.J., McMullin M.F., Scott L.M., Tapper W., Silver R.T., Oscier D., Harrison C.N., Grallert H., Kisialiou A., Strike P., Chase A.J., Green A.R., Cross N.C.,
Blood 115:4517-4523(2010)
The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang S.J., Qiu H.X., Li J.Y., Shi J.Y., Xu W.,
Int J Lab Hematol 32:381-386(2010)
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Pardanani A., Lasho T.L., Finke C.M., Mai M., McClure R.F., Tefferi A.,
Leukemia 24:1146-1151(2010)
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.
Patnaik M.M., Lasho T.L., Finke C.M., Gangat N., Caramazza D., Holtan S.G., Pardanani A., Knudson R.A., Ketterling R.P., Chen D., Hoyer J.D., Hanson C.A., Tefferi A.,
Leukemia 24:1283-1289(2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., Pieri L., Finke C.M., Kilpivaara O., Wadleigh M., Mai M., McClure R.F., Gilliland D.G., Levine R.L., Pardanani A., Vannucchi A.M.,
Leukemia 24:1302-1309(2010)
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.
Guglielmelli P., Biamonte F., Spolverini A., Pieri L., Isgro A., Antonioli E., Pancrazzi A., Bosi A., Barosi G., Vannucchi A.M.,
Leukemia 24:1533-1537(2010)
Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC).
Chen W.M., Yu B., Zhang Q., Xu P.,
J Biol Chem 285:26697-26709(2010)
Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.
Beer P.A., Ortmann C.A., Stegelmann F., Guglielmelli P., Reilly J.T., Larsen T.S., Hasselbalch H.C., Vannucchi A.M., Moller P., Dohner K., Green A.R.,
Haematologica 95:2153-2156(2010)
JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia.
Kim H.J., Jang J.H., Yoo E.H., Kim H.J., Ki C.S., Kim J.W., Kim S.H.,
Korean J Lab Med 30:474-476(2010)
Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu C.H., Shen Y.J., Lai W.C., Tsai W.H., Hsu H.C.,
J Chin Med Assoc 73:530-532(2010)
PKC plays a crucial roles in c-mpl gene expression in megakaryoblastic cells.
Sunohara M., Morikawa S., Murata H., Fuse A., Sato I.,
Okajimas Folia Anat Jpn 87:151-154(2010)
CAMT in a female with developmental delay, facial malformations and central nervous system anomalies.
Martinon-Torres N., Vazquez-Donsion M., Loidi L., Couselo J.M.,
Pediatr Blood Cancer 56:452-453(2011)
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.
Pietra D., Brisci A., Rumi E., Boggi S., Elena C., Pietrelli A., Bordoni R., Ferrari M., Passamonti F., De Bellis G., Cremonesi L., Cazzola M.,
Haematologica 96:607-611(2011)
MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W., Zhang X., Wang X., Zhang Z., Yeh C.H., Uyeji J., Albitar M.,
Diagn Mol Pathol 20:34-39(2011)
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation.
Matthews E.E., Thevenin D., Rogers J.M., Gotow L., Lira P.D., Reiter L.A., Brissette W.H., Engelman D.M.,
FASEB J 25:2234-2244(2011)
A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population.
Jalas C., Anderson S.L., Laufer T., Martimucci K., Bulanov A., Xie X., Ekstein J., Rubin B.Y.,
Blood Cells Mol Dis 47:79-83(2011)
Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
Chen X., Qi X., Tan Y., Xu Z., Xu A., Zhang L., Wang H.,
Blood Cells Mol Dis 47:67-71(2011)
Novel multiplex bead-based assay with LNA-modified probes for detection of MPL exon 10 mutations.
Ivanova M.I., Shivarov V.S., Hadjiev E.A., Naumova E.J.,
Leuk Res 35:1120-1123(2011)
Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E., Miyakawa Y., Yamane A., Okamoto S.,
Exp Hematol 39:829-836(2011)
Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis.
Pardanani A., Lasho T.L., Finke C.M., Tefferi A.,
Am J Hematol 86:701-702(2011)
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A., Guglielmelli P., Lasho T.L., Pancrazzi A., Finke C.M., Vannucchi A.M., Tefferi A.,
Leukemia 25:1834-1839(2011)
Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.
Boiocchi L., Orazi A., Ghanima W., Arabadjief M., Bussel J.B., Geyer J.T.,
Mod Pathol 25:65-74(2012)
Orientation-specific signalling by thrombopoietin receptor dimers.
Staerk J., Defour J.P., Pecquet C., Leroy E., Antoine-Poirel H., Brett I., Itaya M., Smith S.O., Vainchenker W., Constantinescu S.N.,
EMBO J 30:4398-4413(2011)
[STAT5 phosphorylation levels of erythropoietin and thrombopoietin receptors in CD34(+)CD59(-) and CD34(+)CD59(+) bone marrow cells of patients with paroxysmal nocturnal hemoglobinuria].
Wang D., Fu R., Ruan E.B., Qu W., Liang Y., Wang H.Q., Wang J., Li L.J., Liu H., Wang H.L., Zhang T., Liu H., Wu Y.H., Xing L.M., Wang G.J., Wang X.M., Song J., Guan J., Shao Z.H.,
Zhonghua Yi Xue Za Zhi 91:2129-2131(2011)
Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment.
Ballmaier M., Germeshausen M.,
Semin Thromb Hemost 37:673-681(2011)
Exome sequencing identifies MPL as a causative gene in familial aplastic anemia.
Walne A.J., Dokal A., Plagnol V., Beswick R., Kirwan M., de la Fuente J., Vulliamy T., Dokal I.,
Haematologica 97:524-528(2012)
Novel pathways to erythropoiesis induced by dimerization of intracellular C-Mpl in human hematopoietic progenitors.
Parekh C., Sahaghian A., Kim W., Scholes J., Ge S., Zhu Y., Asgharzadeh S., Hollis R., Kohn D., Ji L., Malvar J., Wang X., Crooks G.,
Stem Cells 30:697-708(2012)
The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
Chou F.S., Griesinger A., Wunderlich M., Lin S., Link K.A., Shrestha M., Goyama S., Mizukawa B., Shen S., Marcucci G., Mulloy J.C.,
Blood 120:709-719(2012)
[EPOR and TPOR expressions on CD34+ CD59- and CD34+ CD59+ bone marrow cells from patients with paroxysmal nocturnal hemoglobinuria].
Wang D., Fu R., Ruan E.B., Qu W., Liang Y., Wang H.Q., Wang J., Li L.J., Liu H., Wang H.L., Zhang T., Liu H., Wu Y.H., Xing L.M., Wang G.J., Wang X.M., Song J., Guan J., Sha Z.H.,
Zhonghua Xue Ye Xue Za Zhi 32:543-547(2011)
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Pecquet C., Diaconu C.C., Staerk J., Girardot M., Marty C., Royer Y., Defour J.P., Dusa A., Besancenot R., Giraudier S., Villeval J.L., Knoops L., Courtoy P.J., Vainchenker W., Constantinescu S.N.,
Blood 119:4625-4635(2012)
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D., Casetti I., Da Via M.C., Elena C., Milanesi C., Rumi E.,
Am J Hematol 87:746-747(2012)
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Pulikkan J.A., Madera D., Xue L., Bradley P., Landrette S.F., Kuo Y.H., Abbas S., Zhu L.J., Valk P., Castilla L.H.,
Blood 120:868-879(2012)
Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases.
He X., Chen Z., Jiang Y., Qiu X., Zhao X.,
J Hematol Oncol 6:11-11(2013)
Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.
Defour J.P., Itaya M., Gryshkova V., Brett I.C., Pecquet C., Sato T., Smith S.O., Constantinescu S.N.,
Proc Natl Acad Sci U S A 110:2540-2545(2013)
MPL Baltimore mutation and thrombocytosis: case report and literature review.
Shkalim-Zemer V., Dgany O., Krasnov T., Yacobovich J., Tamary H.,
J Pediatr Hematol Oncol 35:e112-4(2013)
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.
Rumi E., Pietra D., Guglielmelli P., Bordoni R., Casetti I., Milanesi C., Sant'Antonio E., Ferretti V., Pancrazzi A., Rotunno G., Severgnini M., Pietrelli A., Astori C., Fugazza E., Pascutto C., Boveri E., Passamonti F., De Bellis G., Vannucchi A., Cazzola M.,
Blood 121:4388-4395(2013)
Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential.
Gao W., Chen L., Ma Z., Du Z., Zhao Z., Hu Z., Li Q.,
Gastroenterology 145:636-46.e5(2013)
Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling.
Hirata S., Takayama N., Jono-Ohnishi R., Endo H., Nakamura S., Dohda T., Nishi M., Hamazaki Y., Ishii E., Kaneko S., Otsu M., Nakauchi H., Kunishima S., Eto K.,
J Clin Invest 123:3802-3814(2013)
Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.
dos Santos M.T., Mitne-Neto M., Miyashiro K., Chauffaille M.d.e. L., Rizzatti E.G.,
J Clin Pathol 67:176-178(2014)
VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis.
Takyar S., Vasavada H., Zhang J.G., Ahangari F., Niu N., Liu Q., Lee C.G., Cohn L., Elias J.A.,
J Exp Med 210:1993-2010(2013)
The TPO/c-MPL pathway in the bone marrow may protect leukemia cells from chemotherapy in AML Patients.
Dong-Feng Z., Ting L., Yong Z., Cheng C., Xi Z., Pei-Yan K.,
Pathol Oncol Res 20:309-317(2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
Tefferi A., Lasho T.L., Finke C.M., Knudson R.A., Ketterling R., Hanson C.H., Maffioli M., Caramazza D., Passamonti F., Pardanani A.,
Leukemia 28:1472-1477(2014)
Mpl traffics to the cell surface through conventional and unconventional routes.
Cleyrat C., Darehshouri A., Steinkamp M.P., Vilaine M., Boassa D., Ellisman M.H., Hermouet S., Wilson B.S.,
Traffic 15:961-982(2014)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E., Pietra D., Pascutto C., Guglielmelli P., Martinez-Trillos A., Casetti I., Colomer D., Pieri L., Pratcorona M., Rotunno G., Sant'Antonio E., Bellini M., Cavalloni C., Mannarelli C., Milanesi C., Boveri E., Ferretti V., Astori C., Zini R.,
Blood 124:1062-1069(2014)
Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.
Langabeer S.E., Haslam K., Linders J., Percy M.J., Conneally E., Hayat A., Hennessy B., Leahy M., Murphy K., Murray M., Ni Ainle F., Thornton P., Sargent J.,
Fam Cancer 13:659-663(2014)
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R., Levine R.L.,
Best Pract Res Clin Haematol 27:83-93(2014)
A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor.
Belay E., Miller C.P., Kortum A.N., Torok-Storb B., Blau C.A., Emery D.W.,
Blood 125:1025-1033(2015)
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.
Shirane S., Araki M., Morishita S., Edahiro Y., Takei H., Yoo Y., Choi M., Sunami Y., Hironaka Y., Noguchi M., Koike M., Noda N., Ohsaka A., Komatsu N.,
Haematologica 100:e46-8(2015)
Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl.
Xiao N., Laha S., Das S.P., Morlock K., Jesneck J.L., Raffel G.D.,
Blood 125:941-948(2015)
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi M.C., Carobbio A., Cervantes F., Isola I.M., Vannucchi A.M., Guglielmelli P., Rambaldi A., Finazzi G., Barosi G., Barbui T.,
Leukemia 29:1209-1210(2015)
JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Posfai E., Marton I., Kiraly P.A., Kotosz B., Kiss-Laszlo Z., Szell M., Borbenyi Z.,
Pathol Oncol Res 21:751-758(2015)
The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N., Galindo-Becerra S., Garces-Eisele J., Colunga-Pedraza P., Guzman-Olvera V., Reyes-Nunez V., Ruiz-Delgado G.J., Ruiz-Arguelles G.J.,
Hematol Oncol Stem Cell Ther 8:16-21(2015)
Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs.
Qi X., De Stefano V., Guo X., Fan D.,
Thromb Haemost 113:1378-1380(2015)
Flow cytometric detection of MPL (CD110) as a diagnostic tool for differentiation of congenital thrombocytopenias.
Ballmaier M., Holter W., Germeshausen M.,
Haematologica 100:e341-4(2015)
Essential thrombocythemia with Mpl W515 K mutation in a child presenting with Budd-Chiari syndrome.
Tokgoz H., Caliskan U., Yuksekkaya H.A., Kucukkaya R.,
Platelets 26:805-808(2015)
The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y., Liu E., Sun Q., Ma J., Li Q., Cao Z., Wang J., Jia Y., Zhang H., Song Z., Ai X., Shi L., Feng X., Li C., Wang J., Ru K.,
Am J Clin Pathol 144:165-171(2015)
Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Mela Osorio M.J., Ferrari L., Goette N.P., Gutierrez M.I., Glembotsky A.C., Maldonado A.C., Lev P.R., Alvarez C., Korin L., Marta R.F., Molinas F.C., Heller P.G.,
Eur J Haematol 96:435-442(2016)
Robust hematopoietic progenitor cell commitment in the presence of a conflicting cue.
Shah N.A., Levesque M.J., Raj A., Sarkar C.A.,
J Cell Sci 128:3009-3017(2015)
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Wang L., Cai W., Zhang W., Chen X., Dong W., Tang D., Zhang Y., Ji C., Zhang M.,
Oncotarget 6:27490-27504(2015)
Severe Clinical Course in a Patient with Congenital Amegakaryocytic Thrombocytopenia Due to a Missense Mutation of the c-MPL Gene.
Ok Bozkaya I., Yaralı N., Isık P., Unsal Sac R., Tavil B., Tunc B.,
Turk J Haematol 32:172-174(2015)
Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.
Nussenzveig R.H., Pham H.T., Perkins S.L., Prchal J.T., Agarwal A.M., Salama M.E.,
Leuk Lymphoma 57:1429-1435(2016)
Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.
Defour J.P., Chachoua I., Pecquet C., Constantinescu S.N.,
Leukemia 30:1214-1216(2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.
Cabagnols X., Favale F., Pasquier F., Messaoudi K., Defour J.P., Ianotto J.C., Marzac C., Le Couedic J.P., Droin N., Chachoua I., Favier R., Diop M.K., Ugo V., Casadevall N., Debili N., Raslova H., Bellanne-Chantelot C., Constantinescu S.N., Vainchenker W.,
Blood 127:333-342(2016)
C-Mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-dependent JAK-STAT signaling.
Sasazawa Y., Sato N., Suzuki T., Dohmae N., Simizu S.,
Biochem Biophys Res Commun 468:262-268(2015)
Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M., Yamaguchi H., Usuki K., Kobayashi Y., Kawata E., Kuroda J., Kimura S., Tajika K., Gomi S., Arima N., Mori S., Ito S., Koizumi M., Ito Y., Wakita S., Arai K., Kitano T., Kosaka F., Dan K., Inokuchi K.,
Leuk Res 40:68-76(2016)
His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor.
Leroy E., Defour J.P., Sato T., Dass S., Gryshkova V., Shwe M.M., Staerk J., Constantinescu S.N., Smith S.O.,
J Biol Chem 291:2974-2987(2016)
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I., Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Koay A., Raslova H., Courtoy P.J., Choong M.L., Plo I., Vainchenker W., Kralovics R., Constantinescu S.N.,
Blood 127:1325-1335(2016)
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M., Yang Y., Masubuchi N., Hironaka Y., Takei H., Morishita S., Mizukami Y., Kan S., Shirane S., Edahiro Y., Sunami Y., Ohsaka A., Komatsu N.,
Blood 127:1307-1316(2016)
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala Y.C., Lasho T.L., Gangat N., Finke C., Barraco D., Haider M., Abou Hussein A.K., Hanson C.A., Ketterling R.P., Pardanani A., Tefferi A.,
Am J Hematol 91:503-506(2016)
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S., Abdelfattah N.S., Chen E., Perales-Paton J., Rosen E.A., Ko A., Peisker F., Florescu N., Giannini S., Wolach O., Morgan E.A., Tothova Z., Losman J.A., Schneider R.K., Al-Shahrour F., Mullally A.,
Cancer Discov 6:368-381(2016)
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L., Schubert C., Kohler J., Schemionek M., Isfort S., Brummendorf T.H., Koschmieder S., Chatain N.,
J Hematol Oncol 9:45-45(2016)
Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis.
Rashidi A., Heusel J.W., Oh S.T.,
Blood Cells Mol Dis 60:1-2(2016)
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.
Haider M., Elala Y.C., Gangat N., Hanson C.A., Tefferi A.,
Blood Cancer J 6:e487-e487(2016)
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F., Beaufils N., Calleja A., Raynaud S., Gabert J.,
J Mol Diagn 19:92-98(2017)
JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.
Lin C.H., Kaushansky K., Zhan H.,
Blood Cells Mol Dis 62:42-48(2016)
FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
Ebrahim E.K., Assem M.M., Amin A.I., Kamel M.M., El Meligui Y.M., Metwally A.M.,
Ann Clin Lab Sci 46:592-600(2016)
An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.
Favale F., Messaoudi K., Varghese L.N., Boukour S., Pecquet C., Gryshkova V., Defour J.P., Albu R.I., Bluteau O., Ballerini P., Leverger G., Plo I., Debili N., Raslova H., Favier R., Constantinescu S.N., Vainchenker W.,
Blood 128:3146-3158(2016)
A novel germ-line mutation of c-mpl gene in a sporadic case of essential thrombocythemia.
Lombardi A.M., Ferrari S., Barzon I., Navaglia F., Fabris F., Vianello F.,
Blood Cells Mol Dis 64:51-52(2017)
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
Chen C.C., Hsu C.C., Huang C.E., Chen Y.Y., Lung J., Ho H.Y., Li C.P., Lee J.D.,
Curr Neurovasc Res 14:222-231(2017)
Impact of molecular residual disease post allografting in myelofibrosis patients.
Wolschke C., Badbaran A., Zabelina T., Christopeit M., Ayuk F., Triviai I., Zander A., Alchalby H., Bacher U., Fehse B., Kroger N.,
Bone Marrow Transplant 52:1526-1529(2017)
Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
Araki M., Komatsu N.,
Cancer Sci 108:1907-1912(2017)
[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].
Melikyan A.L., Subortseva I.N., Sudarikov A.B., Kovrigina A.M., Gilyazitdinova E.A., Kolosheinova T.I., Abdullaev A.O., Treglazova S.A.,
Ter Arkh 89:4-9(2017)
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda M.J., Bragos I.M., Calvo K.L., Williams G.M., Carbonell M.M., Pratti A.F.,
Hematology 23:208-211(2018)
JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.
Wong W.J., Hasserjian R.P., Pinkus G.S., Breyfogle L.J., Mullally A., Pozdnyakova O.,
Haematologica 103:e63-e68(2018)
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.
Mansier O., Luque Paz D., Ianotto J.C., Le Bris Y., Chauveau A., Boyer F., Conejero C., Fitoussi O., Riou J., Adiko D., Touati M., Chauzeix J., Viallard J.F., Bene M.C., Giraudier S., Ugo V., Lippert E.,
Am J Hematol 93:E84-E86(2018)
Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Yoshida H., Yamada H., Nogami W., Dohi K., Kurino-Yamada T., Sugiyama K., Takahashi K., Gahara Y., Kitaura M., Hasegawa M., Oshima I., Kuwabara K.,
Exp Hematol 59:30-39.e2(2018)
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S., Abdelfattah N.S., Baral A.J., Beeson D., Rivera J.F., Ko A., Florescu N., Birrane G., Chen E., Mullally A.,
Blood 131:782-786(2018)
Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia.
Li S., Shao J., Xia M., Zhang N., Yang J., Li H., Jiang H.,
Hematology 23:433-438(2018)
A novel frameshift mutation in the MPL gene in congenital amegakaryocytic thrombocytopenia.
Liu R., Jin C., Huang B., Wu J., Shi X.,
Pediatr Blood Cancer 65:e26961-e26961(2018)
Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes.
Alvarez-Larran A., Martinez D., Arenillas L., Rubio A., Arellano-Rodrigo E., Hernandez Boluda J.C., Papaleo N., Caballero G., Martinez C., Ferrer-Marin F., Mata M.I., Perez-Encinas M., Duran M.A., Alonso J.M., Carreno-Tarragona G., Alonso J.M., Noya S., Magro E., Rozman M.,
J Clin Pathol 71:975-980(2018)
Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.
Lang T., Nie Y., Wang Z., Huang Q., An L., Wang Y., Wufuer G., Maimaiti A., Fu L., Li Y., Zhang X., Aisimutula A., Wang X., Zhu L., Liu H., Mao M.,
J Int Med Res 46:4650-4659(2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Grinfeld J., Nangalia J., Baxter E.J., Wedge D.C., Angelopoulos N., Cantrill R., Godfrey A.L., Papaemmanuil E., Gundem G., MacLean C., Cook J., O'Neil L., O'Meara S., Teague J.W., Butler A.P., Massie C.E., Williams N., Nice F.L., Campbell P.J.,
N Engl J Med 379:1416-1430(2018)
The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters.
Defour J.P., Levy G., Leroy E., Smith S.O., Constantinescu S.N.,
Leukemia 33:563-564(2019)
CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.
Yan Z., Ohuchida K., Zheng B., Okumura T., Takesue S., Nakayama H., Iwamoto C., Shindo K., Moriyama T., Nakata K., Miyasaka Y., Ohtsuka T., Mizumoto K., Oda Y., Hashizume M., Nakamura M.,
J Cancer Res Clin Oncol 145:1147-1164(2019)
Indirubin regulates MPL and TNF expression in peripheral blood mononuclear cells from patients with primary immune thrombocytopenia.
Shao K., Wang T., Li T., Zhang A., Cai M., Zhao G., Fu Q., Wang Q., Liu X., Hou M.,
Exp Hematol 73:18-24(2019)
Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
Brooks S.A., Kim D.M., Morse S.J., Nguyen Q.H., Craver B.M., Lai H.Y., Fleischman A.G.,
Leuk Res 82:11-14(2019)
Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S., Stengel R., Jaekel N., Wang S.Y., Franke G.N., Roskos M., Schneider M., Niederwieser D., Al-Ali H.K.,
Genes Chromosomes Cancer 58:747-755(2019)
Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
Masubuchi N., Araki M., Yang Y., Hayashi E., Imai M., Edahiro Y., Hironaka Y., Mizukami Y., Kihara Y., Takei H., Nudejima M., Koike M., Ohsaka A., Komatsu N.,
Leukemia 34:499-509(2020)
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu H.A., Thao T.T., Dong C.V., Vuong N.L., Chuong H.Q., Van P.N.T., Nghia H., Binh N.T., Dung P.C., Xinh P.T.,
Asian Pac J Cancer Prev 20:2775-2780(2019)
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning.
Bridgford J.L., Lee S.M., Lee C.M.M., Guglielmelli P., Rumi E., Pietra D., Wilcox S., Chhabra Y., Rubin A.F., Cazzola M., Vannucchi A.M., Brooks A.J., Call M.E., Call M.J.,
Blood 135:287-292(2020)
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.
de Sauvage F.J., Hass P.E., Spencer S.D., Malloy B.E., Gurney A.L., Spencer S.A., Darbonne W.C., Henzel W.J., Wong S.C., Kuang W.-J., Oles K.J., Hultgren B., Solberg L.A. Jr., Goeddel D.V., Eaton D.L.,
Nature 369:533-538(1994)